| Prevalence | 5-6 per 100,000 population[2] |
| Incidence | 0.5-1.0 per 100,000 annually[2] |
| Age of onset | Typically 60-65 years[2] |
| Disease duration | Median 6-9 years[2] |
| MAPT H1 haplotype | Strongest genetic risk factor[3] |
| C9orf72 expansions | Occasionally found in PSP-FTD spectrum[3] |
| Familial aggregation | Rare but reported in some families[3] |
| Substantia nigra | Pars compacta degeneration[4] |
| Globus pallidus | Internal segment (GPi) involvement[4] |
| Subthalamic nucleus | Neuronal loss[4] |
| Superior colliculus | Vertical gaze center[4] |
| Periaqueductal gray | Oculomotor control[4] |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
No AI portrait yet
No comments yet. Be the first to comment!